ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2835

Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus

Michelle Petri1, Wei Fu1, Ann Ranger2, Normand Allaire2, Patrick Cullen3 and Laurence S Magder4, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Biogen Idec, Cambridge, MA, 3Biogen Idec, Cambridge, MD, 4Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Gene Expression and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided with changes in SLE disease activity.

Methods: 243 patients with SLE were evaluated for disease activity, serological parameters and peripheral blood gene signatures in clinic visits that occurred between 2009 and 2012. 143 SLE patients contributed two visits, 40 patients contributed three visits and 60 patients contributed four or more visits. Levels of the BAFF gene transcript, plasma cell signature, Interferon (IFN) signature and the low density granulocytes (LDG)-associated neutrophil gene signature were assessed in PAX-gene-preserved peripheral blood by global microarray. For multi-gene signatures, the geometric mean of component expression was calculated. The stability of repeated measures of gene expression was quantified using intra-class correlation coefficients (ICC). SLE disease activity was measured using the Physicians Global Assessment (PGA) and the SELENA-SLEDAI index and its components. Using a mixed effects regression model we assessed: 1) the association between a patient’s average gene signature expression over time and disease activity, and 2) the association between a patient’s changes in gene expression over time and changes in disease activity.

Results: Gene expression signatures showed more within-person stability than systolic blood pressure. The IFN signature exhibited the most stability. Patients with high levels of BAFF and IFN transcripts tended to have significantly higher levels of musculoskeletal disease, skin disease, anti-dsDNA, and ESR, and lower levels of complement. However, changes in BAFF or IFN gene signatures were not associated with changes in disease activity. The same associations were seen between the LDG gene signature and disease activity. However, when LDG increased, complement tended to increase. Patients with high levels of plasma cell gene signature tended to have higher levels of anti-dsDNA and lower levels of complement. However, unlike the other gene signatures, changes in plasma cell gene signature significantly coincided with changes in anti-dsDNA and complement.

Conclusion: The gene expression signatures were relatively stable within patients over time. BAFF and IFN gene expression were markers of patients with generally higher disease activity, but changes in these gene signatures did not coincide with changes in disease activity. The plasma cell gene signature expression tracked with the traditional SLE serologic markers of anti-dsDNA and complement.


Disclosure: M. Petri, EMD Serono, 5,Exagen, 2,Janssen, 5,GSK, 5,AstraZeneca, 2,Inova Diagnostic, 5,Novartis, 5,Amgen Inc., 5,Decision Resources, 5,Medscape, 5,Eli Lilly and Co., 5,Quintiles, 5; W. Fu, None; A. Ranger, Biogen Idec, 3; N. Allaire, Biogen Idec, 3; P. Cullen, Biogen Idec, 1, 3; L. S. Magder, None.

To cite this abstract in AMA style:

Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS. Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/association-between-changes-in-gene-signature-expression-and-disease-activity-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-changes-in-gene-signature-expression-and-disease-activity-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology